Navigation Links
Aridis Pharmaceuticals Expands Patent Portfolio for Several Fully Human Monoclonal Antibodies Against Infectious Disease Targets
Date:2/24/2016

SAN JOSE, Calif., Feb. 24, 2016 /PRNewswire/ -- Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today that in addition to the previously announced European Patent Office (EPO) patent issuance, the U.S. Patent and Trademark Office has issued Aridis' patent covering composition-of-matter, method of production and method of treatment for AR-301 (Salvecin™).

AR-301, a fully human monoclonal antibody (mAb) that neutralizes Staphylococcus aureus alpha-toxin, is currently being evaluated in a Phase 2a clinical trial across the U.S. and several countries in Europe.  AR-301 is being tested as an adjunctive therapy to standard of care antibiotics to treat hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) and severe community-acquired pneumonia (CAP).  AR-301 was identified and developed through Aridis' propriety MabIgX™ technology by generating a hybridoma clone from B-cells of a recovered S. aureus bacteremia patient.  The antibody works by neutralizing S. aureus alpha-toxin, which is a critical factor involved in the establishment and persistence of S. aureus infection.

Additionally, the patents covering Aridis' human mAbs against the emerging Gram-negative bacterium Acinetobacter baumannii (A. baumannii), "AR-401," have also received notices of allowance in Europe and the U.S.

Vu Truong, Ph.D., Founder and Chief Executive Officer of Aridis, stated, "We are delighted to have successfully secured expanded patent protection for AR-301 and AR-401.  We are confident that the use of monoclonal antibodies to treat antibiotic resistant pathogens can have a broad impact on reducing healthcare costs by providing additional protection against infections.  The issuance of these patents adds to our already robust intellectual property estate covering our novel therapeutic antibodies, as well as our antibody discovery platform MabIgX®. Furthermore, significant progress has also been made toward the near-term allowance of patent application for Aridis' novel fully human monoclonal antibody against respiratory syncytial virus (RSV), AR-201."

About Aridis Pharmaceuticals, Inc.
Aridis is a privately held biopharmaceutical company applying proprietary monoclonal antibody discovery technology MabIgX™ to produce novel infectious disease focused therapies.  Aridis' product pipeline includes AR-101 (Aerumab™) anti-Pseudomonas aeruginosa LPS human monoclonal antibody; AR-301 (Salvecin™) anti-Staphylococcus aureus human monoclonal antibody to treat acute pneumonia; Aerucin™, a broadly reactive anti-Pseudomonas aeruginosa human monoclonal antibody initially being developed to treat acute pneumonia; Panaecin™, a small molecule anti-infective gallium compound with broad spectrum activities against bacteria, viruses, and fungi; AR- 401 anti-Acinetobacter baumannii human monoclonal antibody; and AR-201 anti-RSV human monoclonal antibody.

Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties.  Such forward-looking statements include statements relating to the therapeutic applications of Aerumab™ (AR-101), Salvecin™ (AR-301), Aerucin™, Panaecin™, AR-401, AR-201, Aridis' proprietary formulation and delivery technologies, about Aridis' strategy, pre-clinical and clinical programs, and ability to identify and develop drugs, as well as other statements that are not historical facts. Actual events or results may differ materially from Aridis' expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the timing, success and cost of Aridis' research and clinical studies and its ability to obtain additional financing.  These forward-looking statements represent Aridis' judgment as of the date of this release. Aridis disclaims any intent or obligation to update these forward-looking statements.

Contacts:

Tiberend Strategic Advisors, Inc. 
Joshua Drumm, Ph.D. (investors) 
jdrumm@tiberend.com 
(212) 375-2664

Andrew Mielach (media)
amielach@tiberend.com 
(212) 375-2694

 


'/>"/>
SOURCE Aridis Pharmaceuticals, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board
2. Aridis Pharmaceuticals Adds Craig Gibbs, Ph.D., MBA, to Board of Directors
3. Aridis Pharmaceuticals Expands Phase 2a Trial Into the U.S. for Monoclonal Antibody AR-301 for the Treatment of Acute Pneumonia
4. Aridis Pharmaceuticals Appoints Fred Kurland as Chief Financial Officer
5. Aridis Pharmaceuticals Receives FDA Fast Track Designation for AR-301 for Acute Pneumonia caused by Staphylococcus aureus
6. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
7. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
8. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
9. Access Pharmaceuticals Reports First Quarter Results
10. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
11. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... Ohio , April 18, 2017  Cardinal Health ... Non-GAAP 1 fiscal 2017 earnings per share (EPS) ... and 2019.  This is in conjunction with this morning,s ... Deep Vein Thrombosis and Nutritional Insufficiency businesses. ... from continuing operations will be at the bottom of ...
(Date:4/18/2017)... DALLAS , April 18, 2017 Viverae ... proud to announce the integration of IBM ® ... platform to deliver targeted communications for a personalized experience. ... meaningful actions on their health in real time. The ... that matter most to members, wherever they are in ...
(Date:4/18/2017)... -- Astute Medical, Inc., developer of biomarkers for better healthcare, ... the 2017 National Kidney Foundation (NKF) Spring Clinical ... 22. Physicians will present data on two biomarkers, ... acute kidney injury (AKI) during the management of patients ... Elevated levels of TIMP-2 and IGFBP-7 have been shown ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... The world-class designers of Happy ... their novel lifesaving device for the everyday use of parents worldwide. It is ... to read a child’s vital signs, and detect unusual symptoms or physical patterns. ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... and credentialing solutions, today announced that Kyle Allain has joined the company as ... Management sales and operations, including provider, payor and managed care solutions. , ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... recognize elevated anxiety levels in people with addiction who are served by MAP’s ... a biosensing wearable device that monitors heart and breath rates to identify anxiety ...
(Date:4/24/2017)... CA (PRWEB) , ... April 24, 2017 , ... As ... is worth a thousand words. The good news for single women is that she ... Attraction," which is available on April 25th. Joan's insight, personal experiences and sparkling sense ...
(Date:4/24/2017)... ... 2017 , ... Donna Parker, L. Ac. reads all sorts of books on ... to be very practical. She wanted to write a guide/workbook that would give readers ... It prompted her in writing “ A Clear Path to a Vibrant Life : ...
Breaking Medicine News(10 mins):